{"status": "OK", "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved.", "response": {"docs": [{"word_count": 1291, "slideshow_credits": null, "multimedia": [], "news_desk": "Business/Financial Desk", "pub_date": "1998-01-20T00:00:00Z", "source": "The New York Times", "web_url": "http://www.nytimes.com/1998/01/20/business/new-baldness-drug-is-older-product-at-a-premium-price.html", "blog": [], "_id": "4fd215748eb7c8105d78efb7", "headline": {"main": "New Baldness Drug Is Older Product at a Premium Price"}, "subsection_name": null, "abstract": null, "section_name": "Business", "byline": {"original": "By DAVID J. MORROW", "person": [{"firstname": "David", "lastname": "MORROW", "role": "reported", "rank": 1, "organization": "", "middlename": "J."}]}, "print_page": "1", "document_type": "article", "type_of_material": "News", "keywords": [], "lead_paragraph": "Kenneth Scovotti, a balding 55-year-old manager of a New York City gasoline station, has spent $15,000 for five hair transplants the last four years. So he was elated to learn about Propecia, Merck & Company's new hair-growth drug. ''Whether it works or not, I was determined to try it,'' Mr. Scovotti said. ''The only problem is that it's expensive for a pill.''", "snippet": "Kenneth Scovotti, a balding 55-year-old manager of a New York City gasoline station, has spent $15,000 for five hair transplants the last four years. So he was  elated to learn about Propecia, Merck & Company's new hair-growth drug.    ''Whether it..."}, {"word_count": 1429, "slideshow_credits": null, "multimedia": [], "news_desk": "Foreign Desk", "pub_date": "1998-01-18T00:00:00Z", "source": "The New York Times", "web_url": "http://www.nytimes.com/1998/01/18/world/tobacco-industry-conciliatory-in-us-goes-on-the-attack-in-the-third-world.html", "blog": [], "_id": "4fd204e08eb7c8105d76c6e2", "headline": {"main": "Tobacco Industry, Conciliatory in U.S., Goes on the Attack in the Third World"}, "subsection_name": null, "abstract": "Tobacco companies have agreed to sweeping restrictions in US on cigarette marketing and second-hand smoke and to bolder cancer-warning labels, but they are fighting as hard as ever in third world to convince media, public and policy makers that similar changes are not needed (M)", "section_name": "World", "byline": {"original": "By BARRY MEIER", "person": [{"rank": 1, "firstname": "Barry", "lastname": "MEIER", "role": "reported", "organization": ""}]}, "print_page": "14", "document_type": "article", "type_of_material": "News", "keywords": [{"value": "MARKETING AND MERCHANDISING", "name": "subject"}, {"value": "CANCER", "name": "subject"}, {"value": "LABELING AND LABELS", "name": "subject"}, {"value": "SMOKING AND TOBACCO", "name": "subject"}, {"value": "THIRD WORLD AND DEVELOPING COUNTRIES", "name": "subject"}], "lead_paragraph": "Last August, dozens of journalists from Latin America arrived in Miami as guests of the British-American Tobacco Company, whose Brown & Williamson unit makes popular cigarettes like Kool, Carlton and Lucky Strike. The company paid for the visitors' air fare, hotel rooms and even dinners at expensive restaurants. At meetings like this, the reporters, from countries including Brazil, Argentina, Chile and Peru, heard company officials and paid speakers attack restrictions on smoking and cigarette advertising as scientifically unsound or artifacts of lawsuit-driven societies like the United States'.", "snippet": "Last August, dozens of journalists from Latin America arrived in Miami as guests of the British-American Tobacco Company, whose Brown & Williamson unit makes popular cigarettes like Kool, Carlton and Lucky Strike.    The company paid for the..."}], "meta": {"offset": 0, "hits": 2, "time": 23}}}